Company profile for Locus Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Locus Biosciences is a biotechnology company that develops CRISPR-engineered precision antibacterial products. Our CRISPR-Phage (“crPhage”) platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage. By selectively removing unwanted bacteria while leaving the many species of good bacteria intact, crPhage™ can address the growing set of diseases sho...
Locus Biosciences is a biotechnology company that develops CRISPR-engineered precision antibacterial products. Our CRISPR-Phage (“crPhage”) platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage. By selectively removing unwanted bacteria while leaving the many species of good bacteria intact, crPhage™ can address the growing set of diseases shown to be related to the human microbiome. Locus Biosciences’ high-throughput discovery automation platform and powerful synthetic biology methods enable rapid and modular drug product development against any target.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
523 Davis Drive Suite 350 Morrisville NC 27560
Telephone
Telephone
+1-(919) 495-4510
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251028884212/en/Locus-Biosciences-Enters-Research-Collaboration-to-Develop-Precision-Antibacterial-Therapies-for-Ophthalmic-Infections

BUSINESSWIRE
28 Oct 2025

https://www.globenewswire.com/news-release/2024/08/12/2928291/0/en/Locus-Biosciences-Announces-Positive-Results-from-Part-1-of-ELIMINATE-Phase-2-Trial-of-the-Engineered-Bacteriophage-Therapy-LBP-EC01-Published-in-The-Lancet-Infectious-Diseases.html

GLOBENEWSWIRE
12 Aug 2024

https://www.globenewswire.com//news-release/2024/01/23/2813976/0/en/Locus-Biosciences-Announces-23-9-Million-in-Funding-from-BARDA-to-Support-First-Phase-2-Trial-of-CRISPR-engineered-Bacteriophage-Therapy.html

GLOBENEWSWIRE
23 Jan 2024

https://www.globenewswire.com/news-release/2022/09/13/2514936/0/en/Locus-Biosciences-Announces-First-Patient-Treated-in-the-ELIMINATE-Registrational-Phase-2-3-Trial-of-LBP-EC01-for-Urinary-Tract-Infections.html

GLOBENEWSWIRE
13 Sep 2022
Locus closes $35M financing, zeros in on antibiotic resistance
Locus closes $35M financing, zeros in on antibiotic resistance

19 May 2022

// Gabrielle Masson FIERCEBIOTECH

https://www.fiercebiotech.com/biotech/jj-backed-locus-closes-35m-financing-crispr-based-antimicrobial-drugs

Gabrielle Masson FIERCEBIOTECH
19 May 2022

https://www.globenewswire.com/news-release/2022/05/18/2445897/0/en/Locus-Biosciences-Announces-35-Million-Financing.html

GLOBENEWSWIRE
18 May 2022

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty